Second, for NSCLC with KRAS mutation and RCCC with relatively low malignancy, despite negative PD-L1 expression, albumin-bound paclitaxel and platinum chemotherapy combined with PD-1 monoclonal antibody immunotherapy is an effective treatment option. This evidence concerns the gene ALB and non-small cell lung carcinoma.